Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment
option for locally advanced esophageal cancer (EC). However, only 20% to 40% of EC patients
can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable
prognosis. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising
activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the
combination of toripalimab (an anti-PD-1 antibody) combined with neoadjuvant CRT in locally
advanced esophageal squamous cell carcinoma (ESCC).